Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

NCT02858492 | Completed Phase 2 Results

• 2 other identifiers: 2031682016-000912-13
• Study Type: interventional
• Target: 52
• Locations: 6 countries
• Sites: 16

Brief Summary

This study is the first study with GSK2982772, a receptor-interacting protein-1 (RIP1) kinase inhibitor, in subjects with moderate to severe RA who are currently being treated with disease modifying anti-rheumatic drugs (DMARDs). The primary objective of the study is to investigate the safety and tolerability of repeat oral doses of GSK2982772 in subjects with moderate to severe RA. In addition to the PK, a number of experimental and clinical endpoints will be employed to obtain information on the PD, and preliminary efficacy in subjects with active RA. Although no formal hypothesis will be tested, these endpoints will enable a broader understanding of the mechanism of action and potential for clinical efficacy of GSK2982772 in RA. After a screening period of up to 30 days, approximately 24 subjects will be randomized to receive either GSK2982772 or placebo for 84 days (12 weeks), followed by a follow-up period (28 days). The total duration of participation in the study will be approximately 20 weeks from screening to the last study visit.

Conditions

Arthritis, Rheumatoid

Keywords

efficacy; safety; pharmacokinetics; pharmacodynamics; Rheumatoid Arthritis; autoimmune

Outcome Measures

Primary Outcomes (11)

• Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability

  An AE was any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE. Number of participants with any nSAE or SAE are presented.

  Up to Day 112

• Number of Participants With Worst Case Clinical Chemistry Parameters of Potential Clinical Importance (PCI)

  Clinical chemistry parameters included alanine amino transferase (ALT), albumin, alkaline phosphatase, aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were ALT(high): \>=2\*Upper limit of Normal(ULN) units per liter(U/L), albumin(low): 30 millimoles per liter(mmol/L), alkaline phosphatase(high): \>=2\*ULN U/L, AST(high): \>=2\*ULN U/L, calcium: \<2(low) or \>2.75 mmol/L(high), creatinine (high): increase from Baseline \>44.25 mmol/L, glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and total bilirubin(high): \>=1.5\*ULN micromoles per liter(µmol/L). Participants were counted in the worst case category if their value changes (to low or to high), unless there is no change in their category. Only those clinical chemistry parameters with PCI values (to low and to high) have been presented.

  Up to Day 112

• Number of Participants With Worst Case Hematology Parameters of PCI

  Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and white blood cells (WBCs). PCI ranges were \< 0.075 (decrease from baseline) or \>0.54 proportion of red blood cells in blood (high) for hematocrit, \<25 (low) or \>180 grams per liter (g/L) (high) for hemoglobin, \<0.8 x10\^9 cells per liter (cells/L) for lymphocytes (low), \<100 (low) or \>550 x10\^9 cells/L(high) for platelets, \<1.5 x10\^9 cells/L (low) for total neutrophils and \< 3 (low) or \>20 x10\^9 cells/L (high) for WBCs. Participants were counted in the worst case category that their value changes (to low or to high), unless there is no change in their category. Only those hematology parameters with PCI values (to low and to high) have been presented.

  Up to Day 112

• Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method

  Urine samples were collected to assess glucose, ketones, occult blood and protein by dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters glucose, ketones, occult blood and protein were categorized as 'any increase from Baseline', which imply any increase in their concentrations in the urine sample. Only participants with worst case any increase from Baseline values are presented.

  Up to Day 112

• Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Microscopy Method

  Urine samples were collected to assess glucose, ketones, occult blood and protein by dipstick method. Microscopy was performed only on urine samples showing an abnormality on the dipstick. Microscopy was performed for hyaline casts, red blood cells and white blood cells. Results for microscopy parameters hyaline casts, red blood cells and white blood cells were categorized as 'any increase from Baseline', which imply any increase in their count in the urine sample. Only participants with worst case any increase from Baseline values are presented.

  Up to Day 112

• Change From Baseline in Electrocardiogram (ECG) Heart Rate at Indicated Time Points

  12- lead ECG was measured on each day using an ECG machine that automatically calculated the heart rate and measured PR interval, QRS duration, QT interval, QT interval corrected for heart rate according to either Bazett's formula (QTcB) and QT interval corrected for heart rate according to Fridericia's formula (QTcF). ECG was measured in semi-supine or supine position after 5 minutes rest. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting post-dose value from Baseline value.

  Baseline (Day 1 pre-dose), Days 8, 15, 29, 43, 57, 71 and 85

• Change From Baseline in ECG PR Interval, QRS Duration, QT Interval, QTcB and QTcF at Indicated Time Points

  12- lead ECG was measured on each day using an ECG machine that automatically calculated the heart rate and measured PR interval, QRS duration, QT interval QTcB and QTcF. ECG was measured in semi-supine or supine position after 5 minutes rest. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting post-dose value from Baseline value.

  Baseline (Day 1 pre-dose), Days 8, 15, 29, 43, 57, 71 and 85

• Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time Points

  SBP and DBP were measured in a supine or semi-supine position after approximately 5 minutes rest. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting post-dose value from Baseline value.

  Baseline (Day 1 pre-dose), Days 8, 15, 29, 43, 57, 71 and 85

• Change From Baseline in Respiratory Rate at Indicated Time Points

  Respiratory rate was measured in a supine or semi-supine position after approximately 5 minutes rest. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting post-dose value from Baseline value.

  Baseline (Day 1 pre-dose), Days 8, 15, 29, 43, 57, 71 and 85

• Change From Baseline in Body Temperature at Indicated Time Points

  Body temperature was measured in a supine or semi-supine position after approximately 5 minutes rest. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting post-dose value from Baseline value.

  Baseline (Day 1 pre-dose), Days 8, 15, 29, 43, 57, 71 and 85

• Change From Baseline in Vital Sign-heart Rate at Indicated Time Points

  Vital sign-heart rate was planned to be assessed as a measure of safety and tolerability.

  Baseline (Day 1 pre-dose), Days 8, 15, 29, 43, 57, 71 and 85

Secondary Outcomes (31)

• Pre-dose Plasma Concentrations of GSK2982772 on Days 8 and 43

  Pre-dose on Day 8 and Day 43

• Post-dose Plasma Concentrations of GSK2982772 on Days 1, 8, and 43 at 1, 2, 4 and 6 Hours

  Days 1, 8 and 43: 1, 2, 4 and 6 hours post-dose

• Trough Plasma Concentration of GSK2982772 on Day 85

  Day 85

• Pre-dose Plasma Concentrations of Methotrexate on Days 1, 8 and 43

  Pre-dose on Days 1, 8 and 43

• Percent Change From Baseline in C-Reactive Protein (CRP)

  Baseline (Day 1 pre-dose), Days 43 and 85

Other Outcomes (2)

• Change From Baseline in Joint Volume

  Baseline (Day 1 pre-dose), Days 43 and 85

• Change From Baseline in Enhancing Volume

  Baseline (Day 1 pre-dose), Days 43 and 85

Study Arms (2)

Subjects receiving GSK2982772 60 mg

EXPERIMENTAL

Enrolled subjects will receive GSK2982772 60 mg thrice daily (approximately 8 hours apart) for 84 days.

Drug: GSK2982772 60 mg

Subjects receiving Placebo

EXPERIMENTAL

Enrolled subjects will receive placebo thrice daily (approximately 8 hours apart) for 84 days.

Drug: Placebo

Interventions

GSK2982772 60 mg DRUG

GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.

Subjects receiving GSK2982772 60 mg

Placebo DRUG

Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.

Subjects receiving Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Between 18 and 75 years of age inclusive, at the time of signing the informed consent.
• Subjects that do not have any medical conditions, other than moderate to severe RA, that in the opinion of the Investigator put the subject at unacceptable risk or interfere with study assessments or integrity of the data. These medical conditions should be stable at the time of screening and are expected to remain stable for the duration of the study.
• Subject has had a confirmed diagnosis of rheumatoid arthritis according to the revised 2010 ACR-EULAR classification criteria.
• Disease duration of \>=12 weeks (time from onset of patient-reported symptoms of either pain or stiffness or swelling in hands, feet or wrists) at screening.
• Swollen joint count of \>=4 (28-joint count) and tender joint count \>=4 (28-joint count) at screening.
• Subject has a DAS28 CRP disease activity score of \>= 3.2 and CRP \>= 5.0 mg/liter (L) (\>=4.76 nanomole (nmol)/L) at screening.
• Subject must have received at least 12 weeks of non-biologic DMARD monotherapy or MTX/DMARD combination therapy prior to screening and must be on stable dose throughout the study.
• Subject is naive to any biological therapies for RA or subject may have had previous exposure to a single anti-tumor necrosis factor (TNF) biologic agent which was discontinued for reasons other than primary non-response more than 8 weeks (or 5 half lives whichever is longer) from first dose.
• For subjects who have consented to synovial joint biopsy:
• Subject has an involved knee, wrist, or ankle suitable for biopsy, as assessed by a rheumatologist at screening.
• A body mass index (BMI) within range of 18.5 - 35 kilogram/meter\^2 (Kg/m\^2) (inclusive) at screening.
• Male and female subjects Males: Male subjects with female partners of child bearing potential must comply with the contraception requirements specified in the protocol.
• Females: A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotropin \[HCG\] test), not lactating, and at least one of the following conditions applies:
• Non-reproductive potential as defined as pre-menopausal females with either documented tubal ligation or Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion or Hysterectomy or Documented Bilateral Oophorectomy. For Postmenopausal females as 12 months of spontaneous amenorrhea in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment..
• Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication and until at least 30 days after the last dose of study medication and completion of the follow-up visit.

You may not qualify if:

• Subject with a positive anti-double stranded deoxyribonucleic acid (DNA \[anti-dsDNA\]) and confirmed diagnosis of systemic lupus erythematosus (SLE).
• Subject with current history of Suicidal Ideation Behavior (SIB) as measured using the Columbia Suicide Severity Rating Scale (C-SSRS) or a history of attempted suicide.
• An active infection, or a history of infections as follows:
• Hospitalization for treatment of infection within 60 days before first dose (Day 1).
• Currently on any suppressive therapy for a chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria).
• Use of parenteral (intravenous \[IV\] or intramuscular) antibiotics (antibacterials, antivirals, antifungals, or antiparasitic agents) for an infection within 60 days before first dose.
• A history of opportunistic infections within 1 year of screening (e.g. pneumocystis jirovecii, cytomegalovirus \[CMV\] pneumonitis, aspergillosis). This does not include infections that may occur in immunocompetent individuals, such as fungal nail infections or vaginal candidiasis, unless it is of an unusual severity or recurrent nature.
• Recurrent or chronic infection or other active infection that, in the opinion of the Investigator might cause this study to be detrimental to the patient.
• History of Tuberculosis (TB), irrespective of treatment status.
• A positive diagnostic TB test at screening defined as a positive QuantiFERON-TB Gold test or T-spot test. In cases where the QuantiFERON or T-spot test is indeterminate, the subject may have the test repeated once, but they will not be eligible for the study unless the second test is negative. In cases where the QuantiFERON or T-spot test is positive, but a locally-read follow up chest x-ray, shows no evidence of current or previous pulmonary tuberculosis, the subject may be eligible for the study at the discretion of the Investigator and GSK Medical Monitor.
• Electrocardiogram QT interval corrected for heart rate (QTc) \> 450 milliseconds (msec) or QTc \> 480 msec for subjects with bundle branch block at screening.
• The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or another method, machine or manual over read. The specific formula that will be used to determine eligibility and discontinuation for an individual subject should be determined and documented prior to initiation of the study. In other words, several different formulae cannot be used to calculate the QTc for an individual subject and then the lowest QTc value used to include or discontinue the subject from the trial. For purposes of data analysis, QTcB, QTcF, another QT correction formula, or a composite of available values of QTc will be used.
• Alanine aminotransferase (ALT) \>2x upper limit of normal (ULN) and bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent) at screening.
• Current active or chronic history of liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• Current or history of renal disease or estimated glomerular filtration rate (GFR) by Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) calculation \<60 milliliter (mL)/minute (min)/1.73 m\^2 at screening.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (16)

GSK Investigational Site

Rendsburg, Schleswig-Holstein, 24768, Germany

Location

GSK Investigational Site

Berlin, 10117, Germany

Location

GSK Investigational Site

Rome, Lazio, 00168, Italy

Location

GSK Investigational Site

Verona, Veneto, 37134, Italy

Location

GSK Investigational Site

Bialystok, 15-879, Poland

Location

GSK Investigational Site

Elblag, 82-300, Poland

Location

GSK Investigational Site

Krakow, 31-513, Poland

Location

GSK Investigational Site

Świdnik, 21-040, Poland

Location

GSK Investigational Site

Warsaw, 04-305, Poland

Location

GSK Investigational Site

Ulyanovsk, 432063, Russia

Location

GSK Investigational Site

Yaroslavl, 150030, Russia

Location

GSK Investigational Site

Málaga, Andalusia, 29004, Spain

Location

GSK Investigational Site

A Coruña, 15006, Spain

Location

GSK Investigational Site

Barcelona, 08036, Spain

Location

GSK Investigational Site

Southampton, Hampshire, SO16 6YD, United Kingdom

Location

GSK Investigational Site

London, W12 0NN, United Kingdom

Location

Related Publications (1)

• Weisel K, Berger S, Thorn K, Taylor PC, Peterfy C, Siddall H, Tompson D, Wang S, Quattrocchi E, Burriss SW, Walter J, Tak PP. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis. Arthritis Res Ther. 2021 Mar 16;23(1):85. doi: 10.1186/s13075-021-02468-0.

  PMID: 33726834 BACKGROUND

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

GSK2982772

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

GSKClinicalSupportHD@gsk.com

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 20, 2016
• First Posted: August 8, 2016
• Study Start: October 17, 2016
• Primary Completion: October 22, 2018
• Study Completion: October 22, 2018
• Last Updated: June 15, 2021
• Results First Posted: November 1, 2019

Record last verified: 2021-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
• Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Locations

RU (2); DE (2); GB (2); ES (3); IT (2); PL (5)